Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, RxSight Inc (NASDAQ: RXST) closed at $8.73 up 3.31% from its previous closing price of $8.45. In other words, the price has increased by $3.31 from its previous closing price. On the day, 1.02 million shares were traded. RXST stock price reached its highest trading level at $8.85 during the session, while it also had its lowest trading level at $8.2.
Ratios:
For a deeper understanding of RxSight Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.70 and its Current Ratio is at 13.93. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
On July 10, 2025, Jefferies Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $9.
Wells Fargo Downgraded its Overweight to Equal Weight on July 09, 2025, while the target price for the stock was maintained at $9.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 12 ’25 when Fountain Tamara sold 7,000 shares for $25.71 per share. The transaction valued at 180,002 led to the insider holds 24,793 shares of the business.
TAMARA R FOUNTAIN bought 7,000 shares of RXST for $180,002 on Mar 12 ’25. On Jan 22 ’25, another insider, Maniar Shweta, who serves as the Director of the company, sold 3,519 shares for $30.87 each. As a result, the insider received 108,618 and left with 7,383 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXST now has a Market Capitalization of 357196672 and an Enterprise Value of 141420352. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.43 while its Price-to-Book (P/B) ratio in mrq is 1.28. Its current Enterprise Value per Revenue stands at 0.962 whereas that against EBITDA is -3.596.
Stock Price History:
The Beta on a monthly basis for RXST is 1.15, which has changed by -0.84534985 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, RXST has reached a high of $58.23, while it has fallen to a 52-week low of $6.32. The 50-Day Moving Average of the stock is -11.49%, while the 200-Day Moving Average is calculated to be -63.42%.
Shares Statistics:
For the past three months, RXST has traded an average of 1.29M shares per day and 1373560 over the past ten days. A total of 40.91M shares are outstanding, with a floating share count of 37.48M. Insiders hold about 8.40% of the company’s shares, while institutions hold 93.26% stake in the company. Shares short for RXST as of 1753920000 were 6225276 with a Short Ratio of 4.82, compared to 1751241600 on 5790650. Therefore, it implies a Short% of Shares Outstanding of 6225276 and a Short% of Float of 15.97.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of RxSight Inc (RXST) in the stock market.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.06 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$0.43 and -$0.89 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.58, with 6.0 analysts recommending between -$0.19 and -$1.13.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $25.63M this quarter.It ranges from a high estimate of $28.8M to a low estimate of $24.6M. As of the current estimate, RxSight Inc’s year-ago sales were $35.31MFor the next quarter, 10 analysts are estimating revenue of $28.63M. There is a high estimate of $29.8M for the next quarter, whereas the lowest estimate is $27.4M.
A total of 11 analysts have provided revenue estimates for RXST’s current fiscal year. The highest revenue estimate was $129.5M, while the lowest revenue estimate was $125M, resulting in an average revenue estimate of $125.86M. In the same quarter a year ago, actual revenue was $139.93MBased on 11 analysts’ estimates, the company’s revenue will be $134.29M in the next fiscal year. The high estimate is $142.5M and the low estimate is $122.7M.
